Generally, breast cancer is grouped into subtypes according to therapy, in hormone positive (estrogen- and progesterone-positive tumors) which are treated by hormones, HER2-positive (positive for the human epidermal growth factor receptor 2 (HER2)) which are treated with trastuzumab, and triple-negative tumors, which are negative for estrogen, progesterone, and HER2 receptors and are particularly aggressive, with a higher propensity for metastasis [1]. Here, ERBB2 is linked to breast carcinoma.